Irish biotechnology firm Shire has secured authorisation from the European Commission (EC) to market Veyvondi for the treatment of adults with von Willebrand disease (VWD).

The drug is indicated for bleeding events and the treatment or prevention of surgical bleeding in patients who do not respond to or cannot use desmopressin (DDAVP) therapy alone.

VWD is a common, genetic bleeding disorder caused by a deficiency or dysfunction of von Willebrand Factor (VWF), which is required for normal blood clotting.

Veyvondi is a recombinant von Willebrand Factor (rVWF) therapy. It is designed to selectively target the primary deficiency or dysfunction of VWF.

The therapeutic also enables the body to restore and maintain sufficient levels of Factor VIII (FVIII) in plasma.

Shire chief scientific officer and Research and Development head Andreas Busch said: “The approval in Europe for Veyvondi marks a key milestone in our efforts to tackle unmet medical needs for those living with von Willebrand disease.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“We are excited to take the next steps in ensuring that Veyvondi is widely available across Europe to address the individual needs of those affected by the condition and in need of factor replacement.”

“We are excited to take the next steps in ensuring that Veyvondi is widely available across Europe to address the individual needs of those affected by the condition and in need of factor replacement.”

The EC decision comes after review of results from a Phase I and two Phase III clinical trials conducted in a total of 80 subjects.

During the multi-centre, controlled, randomised, single-blind, dose-escalation Phase I trial, the safety, tolerability and pharmacokinectics (PK) of rVWF:rFVIII were studied in severe VWD patients aged between 18 and 60 years old.

Meanwhile, a multi-centre open-label Phase III study evaluated the PK, safety and efficacy of rVWF:rFVIII and rVWF while treating bleeding episodes in adult subjects.

A separate prospective, open-label, uncontrolled, non-randomised, international multi-centre Phase III trial investigated the haemostatic efficacy and safety of rVWF with or without rFVIII in adult patients undergoing major, minor or oral elective surgical procedures.